In a report released today, Salveen Richter from Goldman Sachs maintained a Hold rating on ACADIA Pharmaceuticals (ACAD - Research Report), with a price target of $15.00. The company's shares closed yesterday at $16.62.Richter covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Bluebird Bio, and Crispr Therapeutics AG. According to TipRanks, Richter has an average return of 30.3% and a 55.26% success rate on recommended stocks. In addition to Goldman Sachs, ACADIA Pharmaceuticals also received a Hold from Citigroup's Neena Bitritto-Garg in a report issued today. However, on the same day, JMP Securities reiterated a Buy rating on ACADIA Pharmaceuticals (NASDAQ: ACAD).
https://www.tipranks.com/news/blurbs/acadia-pharmaceuticals-acad-receives-a-hold-from-goldman-sachs-2?utm_source=advfn.com&utm_medium=referral
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more Acadia Pharmaceuticals Charts.
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more Acadia Pharmaceuticals Charts.